A broader range of indications in rheumatology combined with a Canadian push for biosimilar acceptance bodes well for Merck's Brenzys product.
Expanded indications have been approved for Merck’s Brenzys etanercept biosimilar by Health Canada. Originally approved in 2016 for the treatment of moderate-to-severe rheumatoid arthritis in adults and ankylosing spondylitis, Brenzys now has several additional approved indications: plaque psoriasis (PsO), psoriatic arthritis (PsA), and juvenile idiopathic arthritis (JIA).
Brenzys references Enbrel, which is already indicated by Health Canada for all the above-named indications. The drug is administered by subcutaneous injection.
In its statement about the expanded uses, Merck noted that roughly 1 million residents of Canada live with psoriasis and, of those, at least 10% will go on to develop PsA.
Anti-TNF Drug
Etanercept is a tumor necrosis factor (TNF) blocker that reduces the amount of TNF-alpha made by the body’s immune system. Too much TNF-alpha is a characteristic of PsO, PsA, and JIA. This overproduction leads to painful, swollen joints and the development of thick, red, scaly patches known as psoriatic skin lesions, which can appear on any part of the body. Etanercept helps to ease these conditions.
JIA is the most common type of arthritis in children under the age of 16 and in Canada, roughly 10,000 youths have this condition.
“Merck is committed to providing Canadians with more therapeutic choices for patients and their treaters,” Anna Van Acker, president of Merck Canada, said in the statement.
Under the category of PsO, Canada Health has approved Brenzys for the treatment of adults with chronic moderate-to-severe PsO who are candidates for systemic therapy or phototherapy and also pediatric patients 4 to 17 years of age with chronic severe PsO who are candidates for systemic therapy or phototherapy.
In patients aged 4 to 17 years with an inadequate response to disease-modifying antirheumatic drugs, Brenzys is approved for the treatment of moderate-to-severe polyarticular JIA.
Full Steam on Biosimilars
Various Canadian provinces are moving aggressively toward implementation of biosimilars in an attempt to save money and improve access to health care. British Columbia is furthest ahead with these initiatives and recently reported total savings of $96.6 million, which it plowed back into health system investments that made other forms of care more available for patients.
In the most recent phase of this transition, British Columbia established mandatory switching to biosimilar rituximab for patients in its PharmaCare prescription coverage plan. Other Canadian provinces are following suit with similar switching programs, but the overall usage picture for biosimilars in Canada shows that the market for these drugs remains small.
Biosimilars have 8% of the Canadian market relative to originator products. In the United States, biosimilars command just 2.3% of the biologics marketplace, according to a recent Pfizer presentation.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.